Shares of Medtronic (MDT) have plummeted 40% from their 2021 peak, yet the company is offering a historically high dividend yield of 3.6%. Despite facing challenges with growth and profitability, Medtronic is undergoing a strategic overhaul, including a focus on higher-margin products and the spin-off of its lower-margin diabetes division, MiniMed. This restructuring aims to enhance margins and boost earnings, while the introduction of new products, particularly the Hugo surgical robot, is expected to reinvigorate growth.
For investors, Medtronic’s current valuation presents a potential buying opportunity. The company’s commitment to increasing its dividend annually for 48 years, despite recent modest hikes, signals resilience and a long-term strategy to navigate through difficult periods. As Medtronic aligns its business for future success, Wall Street may reward the stock with a higher valuation.
In summary, savvy investors may want to consider adding Medtronic to their portfolios now, capitalizing on its attractive yield while awaiting a turnaround in business performance.
Source: fool.com